Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2007 May 15:2:25.
doi: 10.1186/1750-1172-2-25.

Central core disease

Affiliations
Review

Central core disease

Heinz Jungbluth. Orphanet J Rare Dis. .

Abstract

Central core disease (CCD) is an inherited neuromuscular disorder characterised by central cores on muscle biopsy and clinical features of a congenital myopathy. Prevalence is unknown but the condition is probably more common than other congenital myopathies. CCD typically presents in infancy with hypotonia and motor developmental delay and is characterized by predominantly proximal weakness pronounced in the hip girdle; orthopaedic complications are common and malignant hyperthermia susceptibility (MHS) is a frequent complication. CCD and MHS are allelic conditions both due to (predominantly dominant) mutations in the skeletal muscle ryanodine receptor (RYR1) gene, encoding the principal skeletal muscle sarcoplasmic reticulum calcium release channel (RyR1). Altered excitability and/or changes in calcium homeostasis within muscle cells due to mutation-induced conformational changes of the RyR protein are considered the main pathogenetic mechanism(s). The diagnosis of CCD is based on the presence of suggestive clinical features and central cores on muscle biopsy; muscle MRI may show a characteristic pattern of selective muscle involvement and aid the diagnosis in cases with equivocal histopathological findings. Mutational analysis of the RYR1 gene may provide genetic confirmation of the diagnosis. Management is mainly supportive and has to anticipate susceptibility to potentially life-threatening reactions to general anaesthesia. Further evaluation of the underlying molecular mechanisms may provide the basis for future rational pharmacological treatment. In the majority of patients, weakness is static or only slowly progressive, with a favourable long-term outcome.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Histopathologic appearance of typical central core disease: NADH-TR, transverse section from the rectus femoris. Marked predominance of dark staining, high oxidative type 1 fibres with cores affecting the majority of fibres. Cores are typically well demarcated and centrally located (→), but may occasionally be multiple and of eccentric location.
Figure 2
Figure 2
* Muscle involvement in the lower limbs in CCD secondary to dominant RYR1 mutations: T1-weighted MR imaging, transverse sections of the proximal thigh (A-C) and the proximal lower leg (D-F) in an eleven (A) and a thirteen year old boy (B,E), and a twelve (C,F) and seventeen year old girl (D). In the thigh (A-C), there is marked increase in abnormal signal within vasti, sartorius and adductor magnus with relative sparing of rectus femoris, adductor longus, gracilis and semitendinosus. In the lower leg, there is increase in abnormal signal in soleus (D-F), and – in more severe cases (E-F) – peroneal group and gastrocnemius medialis. Tibialis anterior and gastrocnemius lateralis are relatively spared. (VL = vastus lateralis, VI = vastus intermedius, VM = vastus medialis, RF = rectus femoris, AL = adductor longus, AM = adductor magnus, S = sartorius, G = gracilis, St = semitendinosus). * Reprinted from Neuromuscul Disord 2004, 14: Jungbluth H, Davis MR, Muller C, Counsell S, Allsop J, Chattopadhyay A, Messina S, Mercuri E, Laing NG, Sewry CA, Bydder G, Muntoni F. Magnetic resonance imaging of muscle in congenital myopathies associated with RYR1 mutations. Pages: 785–790. Copyright Owner Elsevier, Copyright (2004), with permission from Elsevier".

Similar articles

Cited by

References

    1. McKusick VA. In: Mendelian Inheritance in Man. 12th edition. Press TJHU, editor. Baltimore , Johns Hopkins University Press; 1998.
    1. Magee KR, Shy GM. A new congenital non-progressive myopathy. Brain. 1956;79:610–621. doi: 10.1093/brain/79.4.610. - DOI - PubMed
    1. Greenfield JG, Cornman T, Shy GM. The prognostic value of the muscle biopsy in the floppy infant. Brain. 1958;81:461–484. doi: 10.1093/brain/81.4.461. - DOI - PubMed
    1. Dubowitz V, Pearse AG. Oxidative enzymes and phosphorylase in central-core disease of muscle. Lancet. 1960;2:23–24. doi: 10.1016/S0140-6736(60)92665-9. - DOI - PubMed
    1. Wallgren-Pettersson C. Commentationes Physico Mathematicae. University of Helsinki; 1990. Congenital nemaline myopathy: a longitudinal study.

Substances